An about to be published study in the Journal of Atherosclerosis and Thrombosis states incontravertibly that EPA administration, the primary ingredient in Vascepa, reduces the risk of CVD.
From the Paper: "EPA metabolizes into bio-active PGI3 (prostaglandin-3), It is assumed that similar to PGI2, PGI3 inhibits platelet aggregation, vascular contraction, myocardial ischemic injury and arteriosclerosis and induces neoangiogenesis. Therefore, it is speculated that the CVD risk reduction induced by EPA is also associated with the effects of PGI3 in addition to the numerous effects of EPA itself (such as TG reduction, inflammation inhibition and improvements in plasma membrane fluidity). This hypothesis is confirmed by the following findings: an increased CVD risk was found to be associated with a reduction in the EPA/AA ratio, and the EPA/AA ratio was found to be positively correlated with the (PGI2 + PGI3)/TXA2 (thromboxane A2) ratio. It is important to increase the PGI/TXA ratio in order to reduce the incidence of cardiovascular events.".
That is EXACTLY what VASCEPA DOES !!!! And proving that Vascepa causes a reduction in CVD events is what we're looking for from the REDUCE-IT Trial. The results from this study guarantee the results from REDUCE-IT.
Sentiment: Strong Buy
We could have a Cataclysmic Event during ADCOM with this article being on distribution. Maybe almost like the Tungusta Blast or California falling into the Pacific Ocean..
Then my home in AZ would appreciate due to having beach front property. Could happen. :D)
This study is far to robust to be accepted by the hedge fund community. The reality of Vascepa's efficacy doesn't fit the down side trading strategy so it just gets ignored. Now if this were a "meta analysis" on a completely different chemical entity with poor study design and practically no statistical power, then we'd have ourselves a nice 10% sell off.
IMO, the only way up is cash flow positive, or buyout. The latter is a growing possibility.
I went to the web site of this journal and they also have an abstract of an article just released- "Absolute Risk of Cardiovascular Disease and Lipid Management Targets." This Japanese study states that optimum target level of triglycerides in at risk persons is under 150.
I realize this is ridiculous but I have been trying to post the link and I can't figure out how to get past the Yahoo Link Police! HOWEVER....if you look at the news items for AMRN on Yahoo today at 12:09PM "Could New Competition, etc." from Motley Fool, go to MF and read the first comment to Brian Nichols bash piece. The LINK is posted there above my comment to Mr. Nichols. I'm suddenly feeling technologically challenged!
I saw the study about Epa helping reduce inflammation in 2011 journal sent to me by Dr.Barry Sears of ZONE DIET. This study used JELIS data and showed EPA/AA reduction from 1.6 to 0.8 for those on EPADEL -96% EPA .He believes EPA/AA ratio is very high for Americans compared to Japanese as our average is close to 4.0--higher than 3.0 considered OK.
The other part that you mention -pl.give us the title,year/date etc.-so we can read it.
Hi mtdsus, glad tosee you around
same article, Eicosapentaenoic Acid (EPA) Reduces Cardiovascular Events: Relationship with the EPA/Arachidonic Acid Ratio.
Abstract now showing up in Pub Med,
US National Library of Medicine National Institutes of Health,
verified there article in prepublication now, slated to come in
J Atheroscler Thromb. 2013 Sep 18. [i][Epub ahead of print][/i]
full article at
remove *** to leave jp
Highly google-able by title &or author